LEIDEN, THE NETHERLANDS -- (MARKET WIRE) -- October 06, 2006 -- Biotech company Pharming Group NV (“Pharming”) (Euronext: PHARM) (PHARM.AS) announced today that it has received a grant from the US FDA’s Office of Orphan Products Development (OPD) for the clinical development of recombinant human C1 inhibitor (rhC1INH or Rhucin®) for treatment of attacks of hereditary angioedema (HAE).
